EGFR and non-small cell lung carcinoma: Thus, it can be assumed that the presence of co-occurring alterations contributes to the increased spatial and temporal heterogeneity of EGFR-mutant NSCLC [40,41], as some subclones may gain a proliferative advantage under treatment pressure, leading to acquired resistance that may arise sooner or later.